Mergers & Acquisitions
CNP1512 developer accepts offer by U.K.-based Vernalis, plc
Published in Women's Health Weekly, December 22nd, 2005
Vernalis will pay an initial consideration of US$29.5 million, payable in Vernalis shares, and assume certain of Cita's liabilities. Vernalis will also pay deferred consideration in installments of up to US$35 million in either shares or cash (at Vernalis' option) dependent upon achieving certain milestones in respect of the development of Cita's clinical drug candidates CNP1512 and CNP3381. A total of UKP 15.3 million (US$26.2 million) (before expenses) of the initial share consideration has been conditionally placed outside...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Breast Cancer Therapy
Successful lactation is possible after breast-conserving therapy - Cardiology
Diabetes increases risk of in-hospital mortality in women with acute coronary syndrome - Menopause
Hot flashes were linked to anxiety, depression in peri- and post-menopausal women - Rubella Epidemiology
Measles and rubella vaccination efforts are needed among young women in Argentina - Angiography
Breast radiation exposure during pulmonary CT scan exceeds dose for mammography - Apoptosis
Gleditsia sinensis fruit extract induced apoptosis in human carcinoma cells - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
